MAPT and amyloidosis: Additionally, plasma p-tau181 correlates with AD CSF biomarkers, PET-tau and PET-amyloid imaging in DLB; and levels of plasma p-tau181 are higher than controls in both probable DLB and MCI-DLB [86▪,98▪▪,99,100▪].